Get notified when MDT files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Litigation (new) — New $382M antitrust verdict against Medtronic will be automatically trebled to over $1.1B; no liability recorded yet.
NYSE: MDT Medtronic plc 10-Q

Medtronic Q3 revenue +8.7% to $9.02B, but net income falls 11.7% on tariffs and restructuring

Filed February 24, 2026 · Period ending January 23, 2026 · Compared to 10-Q Feb 25, 2025 · ~1 min read

Key Changes

  • high

    Revenue rose 8.7% to $9.02B, but net income fell 11.7% to $1.14B and diluted EPS dropped 11.9% to $0.89.

    Key Financials view on EDGAR →
  • high

    New $382M antitrust verdict against Medtronic will be automatically trebled to over $1.1B; no liability recorded yet.

    Notes: Applied Medical verdict verify on EDGAR →
  • high

    Tariffs expected to hit pre-tax income by $185M in fiscal 2026, mostly in the second half.

    MD&A: Tariff impact verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (CRWD 10-Q) is open in full — no account needed.

Partner

Trade MDT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify